ClinicalTrials.gg
Active, not recruitingNCT05980481Updated Sep 29, 2025

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

A Phase 2/3 interventional study of RC48-ADC(2.5mg/kg) and Trastuzumab in Gastric Cancer, sponsored by RemeGen Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by RemeGen Co., Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing disitamab vedotin in Stomach Neoplasms — 14 open to participants now, 17 under way, 5 of them phase 3. disitamab vedotin · Stomach Neoplasms.

Planned enrollment
4th of 22
201 · median 49
Started
2023
with 7 others
Phase 2/3
2 of 22
1 open now
Primary completion
2025-07
later than 6 of 16 live
Registered
11th of 22
by date
Lead sponsor
7 of 22
RemeGen Co., Ltd.

Among the 22 studies testing disitamab vedotin in Stomach Neoplasms, this one is the 4th largest by planned enrollment, is one of 8 that started in 2023, is one of 2 in phase 2/3, reaches primary completion later than 6 of the 16 other live ones, and was the 11th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

14 of the 22 studies testing disitamab vedotin in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About disitamab vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing disitamab vedotin in Stomach Neoplasms, or all of them as a file.
02

Study summary

This is a Phase II/III, randomized, multicenter, open-label clinical trial designed to evaluate safety and efficacy of RC48-ADC combine with Toripalimab and chemotherapy or RC48-ADC combine with Toripalimab and Trastuzumab as first-line treatment in human epidermal growth factor receptor 2 (HER2)-expression or non-expression participants with locally advanced or metastatic gastric cancer.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary agreement to provide written .
  • Age:18-75 years(including 18 and 75).
  • Predicted survival ≥ 12 weeks.
  • (ECOG) performance status score of 0 or 1.
  • Adequate organ function.
  • All subjects must have inoperable, advanced or gastric or or gastroesophageal adenocarcinoma.
  • Subject must be previously untreated with systemic treatment; Subject that received chemotherapy with recurrence >6 months from completion of therapy are permitted;
  • -expressing status determined by laboratory to be IHC 1+, 2+ or 3+ or IHC0.

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system (CNS) .
  • Known active , active , or (HIV) infection.
  • History of other within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, thyroid cancer ,etal.
  • Known to antibody-drug conjugate(ADC) or PD-(L)1 or any of its components.
  • Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
201 participants (estimated)

Study arms

  • Experimental
    RC48-ADC+Toripalimab+CAPOX (HER2-high expression)

    Participants with HER2-high expression(IHC2+FISH+ or IHC3+) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab every 2 weeks (Q2W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

    Drug: RC48-ADC(2.5mg/kg) · Drug: Toripalimab · Drug: Oxaliplatin(130mg/m2 ) · Drug: Capecitabine(1000mg/m2)

  • Experimental
    RC48-ADC+Toripalimab+Trastuzumab (HER2-high expression)

    Participants with HER2-high expression(IHC2+FISH+ or IHC3+) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab every 2 weeks (Q2W) and Trastuzumab every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

    Drug: RC48-ADC(2.5mg/kg) · Drug: Trastuzumab · Drug: Toripalimab

  • Experimental
    RC48-ADC+Toripalimab+CAPOX (HER2-intermediate/low expression)

    Participants with HER2-intermediate/low expression (IHC 2+/FISH- or IHC 1+) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab every 2 weeks (Q2W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

    Drug: RC48-ADC(2.5mg/kg) · Drug: Toripalimab · Drug: Oxaliplatin(130mg/m2 ) · Drug: Capecitabine(1000mg/m2) · Drug: RC48-ADC(2.0mg/kg) · Drug: Capecitabine(750mg/m2) · Drug: Oxaliplatin(100mg/m2 )

  • Active comparator
    Toripalimab+Trastuzumab+CAPOX (HER2-high expression)

    Participants with HER2-high expression (IHC2+FISH+ or IHC3+) will receive of Toripalimab every 2 weeks (Q2W) , Trastuzumab every 3 weeks (Q3W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

    Drug: Trastuzumab · Drug: Toripalimab · Drug: Oxaliplatin(130mg/m2 ) · Drug: Capecitabine(1000mg/m2)

  • Active comparator
    Toripalimab+CAPOX (HER2- intermediate/low expression)

    Participants with HER2- intermediate/low expression (IHC 2+/FISH- or IHC 1+) will receive of Toripalimab every 2 weeks (Q2W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

    Drug: Toripalimab · Drug: Oxaliplatin(130mg/m2 ) · Drug: Capecitabine(1000mg/m2)

  • Experimental
    RC48-ADC + Toripalimab + Trastuzumab + Capecitabine (HER2-high expression)

    Participants with HER2-high expression(IHC2+FISH+ or IHC3+) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab every 2 weeks (Q2W) , Trastuzumab every 3 weeks (Q3W) and Capecitabine every 3 weeks (Q3W), as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

    Drug: RC48-ADC(2.5mg/kg) · Drug: Trastuzumab · Drug: Toripalimab · Drug: Capecitabine(1000mg/m2)

  • Experimental
    RC48-ADC+Toripalimab+CAPOX (HER2-negative)

    Participants with HER2-negative (IHC0) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab every 2 weeks (Q2W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

    Drug: RC48-ADC(2.5mg/kg) · Drug: Toripalimab · Drug: RC48-ADC(2.0mg/kg) · Drug: Capecitabine(750mg/m2) · Drug: Oxaliplatin(100mg/m2 )

  • Active comparator
    Toripalimab+CAPOX (HER2- negative)

    Participants with HER2- negative (IHC 0) will receive of Toripalimab every 2 weeks (Q2W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

    Drug: Toripalimab · Drug: Oxaliplatin(130mg/m2 ) · Drug: Capecitabine(1000mg/m2)

Interventions

  • DrugRC48-ADC(2.5mg/kg)

    Drug page: Disitamab vedotin

    2.5 mg/kg intravenous infusion every 2 weeks

    Also known as: Disitamab Vedotin

  • First load dose is 8.0mg , then 6.0 mg/kg intravenous infusion every 3 weeks

    Also known as: Trastuzumab Injection

  • 3.0 mg/kg intravenous infusion every 2 weeks

    Also known as: JS001

  • DrugOxaliplatin(130mg/m2 )

    Drug page: Oxaliplatin

    130mg/m2 intravenous infusion Q3W

    Also known as: Oxaliplatin injection

  • DrugCapecitabine(1000mg/m2)

    Drug page: Capecitabine

    1000mg/m2 per os Q3W

    Also known as: Capecitabine Tablets

  • DrugRC48-ADC(2.0mg/kg)

    Drug page: Disitamab vedotin

    2.0 mg/kg intravenous infusion every 2 weeks

    Also known as: Disitamab Vedotin

  • DrugCapecitabine(750mg/m2)

    Drug page: Capecitabine

    750mg/m2 per os Q3W

    Also known as: Capecitabine Tablets

  • DrugOxaliplatin(100mg/m2 )

    100mg/m2 intravenous infusion Q3W

    Also known as: Oxaliplatin injection(100mg/m2 )

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    The objective response rate will be mainly analyzed by according to the RECIST 1.1 standard tumor evaluation by the investigator will be performed).

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Safety(adverse event)

    to evaluate safety including adverse event rate and adverse event grade.

    Time frame: Up to approximately 2 years

  2. Progression-free survival (PFS), evaluated by the investigator

    Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

    Time frame: Up to approximately 2 years

  3. Overall survival (OS)

    Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.

    Time frame: Up to approximately 2 years

  4. Duration of response (DOR)

    DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death

    Time frame: Up to approximately 2 years

  5. Disease Control Rate(DCR)

    DCR is the proportion of subjects with optimal overall response to achieve objective remission or stable disease over the course of the study

    Time frame: Up to approximately 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jul 2025, 23 months.

Of 26 phase 2/3 interventional studies under Stomach Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2023
First posted
Aug 8, 2023
StartActual
Aug 4, 2023
Primary completionActual
Jul 10, 2025
CompletionEst.
Oct 10, 2026
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05980481
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Aug 8, 2023
Start date
Aug 4, 2023
Primary completion
Jul 10, 2025
Completion
Oct 10, 2026 (estimated)
Last update
Sep 29, 2025

Study contacts

Na Su, PhD
study director · RemeGen Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion